Endocrinology and Metabolism (Mar 2019)
Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
- Sang Ouk Chin,
- Cheol Ryong Ku,
- Byung Joon Kim,
- Sung-Woon Kim,
- Kyeong Hye Park,
- Kee Ho Song,
- Seungjoon Oh,
- Hyun Koo Yoon,
- Eun Jig Lee,
- Jung Min Lee,
- Jung Soo Lim,
- Jung Hee Kim,
- Kwang Joon Kim,
- Heung Yong Jin,
- Dae Jung Kim,
- Kyung Ae Lee,
- Seong-Su Moon,
- Dong Jun Lim,
- Dong Yeob Shin,
- Se Hwa Kim,
- Min Jeong Kwon,
- Ha Young Kim,
- Jin Hwa Kim,
- Dong Sun Kim,
- Chong Hwa Kim
Affiliations
- Sang Ouk Chin
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, .Korea
- Cheol Ryong Ku
- Department of Endocrinology, Yonsei University College of Medicine, Seoul, .Korea
- Byung Joon Kim
- Division of Endocrinology, Department of Internal Medicine, Gachon University College of Medicine, Incheon, .Korea
- Sung-Woon Kim
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, .Korea
- Kyeong Hye Park
- Division of Endocrinology and Metabolism, Department of Internal Medicine, National Health Insurance Service Ilsan Hospital, Goyang, .Korea
- Kee Ho Song
- Division of Endocrinology and Metabolism, Department of Medicine, Konkuk University School of Medicine, Seoul, .Korea
- Seungjoon Oh
- Department of Endocrinology and Metabolism, Kyung Hee University School of Medicine, Seoul, .Korea
- Hyun Koo Yoon
- Department of Internal Medicine, Cheil General Hospital & Women's Healthcare Center, Dankook University College of Medicine, Seoul, .Korea
- Eun Jig Lee
- Department of Endocrinology, Yonsei University College of Medicine, Seoul, .Korea
- Jung Min Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, .Korea
- Jung Soo Lim
- Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, .Korea
- Jung Hee Kim
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, .Korea
- Kwang Joon Kim
- Division of Geriatrics, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, .Korea
- Heung Yong Jin
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University and Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, .Korea
- Dae Jung Kim
- Department of Endocrinology and Metabolism, Ajou University School of Medicine, Suwon, .Korea
- Kyung Ae Lee
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University and Biomedical Research Institute of Chonbuk National University Hospital, Jeonju, .Korea
- Seong-Su Moon
- Department of Internal Medicine, Dongguk University College of Medicine, Gyeongju, .Korea
- Dong Jun Lim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, .Korea
- Dong Yeob Shin
- Department of Endocrinology, Yonsei University College of Medicine, Seoul, .Korea
- Se Hwa Kim
- Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, .Korea
- Min Jeong Kwon
- Department of Internal Medicine, Inje University College of Medicine, Busan, .Korea
- Ha Young Kim
- Division of Endocrinology, Department of Internal Medicine, Wonkwang University Sanbon Hospital, Wonkwang University School of Medicine, Gunpo, .Korea
- Jin Hwa Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Chosun University College of Medicine, Gwangju, .Korea
- Dong Sun Kim
- Department of Internal Medicine, Hanyang University College of Medicine, Seoul, .Korea
- Chong Hwa Kim
- Division of Endocrinology and Metabolism, Department of Internal Medicine, Sejong General Hospital, Bucheon, .Korea
- DOI
- https://doi.org/10.3803/EnM.2019.34.1.53
- Journal volume & issue
-
Vol. 34,
no. 1
pp. 53 – 62
Abstract
The Korean Endocrine Society (KES) published clinical practice guidelines for the treatment of acromegaly in 2011. Since then, the number of acromegaly cases, publications on studies addressing medical treatment of acromegaly, and demands for improvements in insurance coverage have been dramatically increasing. In 2017, the KES Committee of Health Insurance decided to publish a position statement regarding the use of somatostatin analogues in acromegaly. Accordingly, consensus opinions for the position statement were collected after intensive review of the relevant literature and discussions among experts affiliated with the KES, and the Korean Neuroendocrine Study Group. This position statement includes the characteristics, indications, dose, interval (including extended dose interval in case of lanreotide autogel), switching and preoperative use of somatostatin analogues in medical treatment of acromegaly. The recommended approach is based on the expert opinions in case of insufficient clinical evidence, and where discrepancies among the expert opinions were found, the experts voted to determine the recommended approach.
Keywords
